Russia launches clinical trials for H5N1 vaccines

May 30, 2006 13:17


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Russian scientists on Tuesday began clinical trial of the country's first vaccines intended to protect humans against the deadly H5N1 bird flu virus, researchers and officials said. The trial involving 120 adult volunteers testing two types of vaccine will end by mid-August, said Anatoly Zverev, the head of the Mechnikov Vaccine and Serum Institute. Anton Katlinsky, head of the Federal Research and Development Company Microgene, said three clinical trial on animals had given reason to "express cautious optimism that the vaccine would prove to be efficient."

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia